The Effect of Chemical Chaperones on the Assembly and Stability of HIV-1 Capsid Protein

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lampel, Ayala ^a   Bram, Yaron ^a   Levy Sakin, Michal ^a   Bacharach, Eran ^a   Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CHAPERONE; METHYLAMINE; TRIMETHYLAMINE OXIDE;

ARTICLE; CONTROLLED STUDY; DENATURATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; STRUCTURE ANALYSIS; ULTRASTRUCTURE; VIRUS CAPSID; VIRUS PARTICLE;

ANTI-HIV AGENTS; CAPSID PROTEINS; HIV-1; KINETICS; MODELS, MOLECULAR; ORGANIC CHEMICALS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84875936845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060867     Document Type: Article

References (58)

1. Gazit E, (2010) Bioinspired chemistry: Diversity for self-assembly. Nat Chem 2: 1010-1011.
2. Whitesides GM, (2003) The 'right' size in nanobiotechnology. Nat Biotechnol 21: 1161-1165.
3. Philp D, Stoddart JF, (1996) Self-Assembly in Natural and Unnatural Systems. Angewandte Chemie International Edition in English 35: 1154-1196.
4. Zhang S, (2003) Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol 21: 1171-1178.
5. Bhalla KN, (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22: 9075-9086.
6. Zlotnick A, Mukhopadhyay S, (2011) Virus assembly, allostery and antivirals. Trends Microbiol 19: 14-23.
7. Mateu MG, (2009) The capsid protein of human immunodeficiency virus: intersubunit interactions during virus assembly. FEBS J 276: 6098-6109.
8. Gottlinger HG, (2001) The HIV-1 assembly machine. AIDS 15: S13-20.
9. Adamson CS, Freed EO, (2007) Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol 55: 347-387.
10. Freed EO, (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251: 1-15.
11. Frankel AD, Young JA, (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67: 1-25.
12. Prevelige PE Jr, (2011) New approaches for antiviral targeting of HIV assembly. J Mol Biol 410: 634-640.
13. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, et al. (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11: 672-675.
14. Campbell S, Vogt VM, (1995) Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol 69: 6487-6497.
15. Ehrlich LS, Agresta BE, Carter CA, (1992) Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J Virol 66: 4874-4883.
16. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI, (2004) Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol 78: 2545-2552.
17. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI, (1999) Assembly and analysis of conical models for the HIV-1 core. Science 283: 80-83.
18. Gross I, Hohenberg H, Krausslich HG, (1997) In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur J Biochem 249: 592-600.
19. Lanman J, Sexton J, Sakalian M, Prevelige PE Jr, (2002) Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol 76: 6900-6908.
20. Vogt VM, (2005) Blocking HIV-1 virus assembly. Nat Struct Mol Biol 12: 638-639.
21. Chen B, Tycko R, (2010) Structural and dynamical characterization of tubular HIV-1 capsid protein assemblies by solid state nuclear magnetic resonance and electron microscopy. Protein Sci 19: 716-730.
22. Li S, Hill CP, Sundquist WI, Finch JT, (2000) Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407: 409-413.
23. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD, (2003) Structural organization of authentic, mature HIV-1 virions and cores. EMBO J 22: 1707-1715.
24. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI, (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450.
25. Ehrlich LS, Liu T, Scarlata S, Chu B, Carter CA, (2001) HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophys J 81: 586-594.
26. Gross I, Hohenberg H, Wilk T, Wiegers K, Grattinger M, et al. (2000) A conformational switch controlling HIV-1 morphogenesis. EMBO J 19: 103-113.
27. von Schwedler UK, Stemmler TL, Klishko VY, Li S, Albertine KH, et al. (1998) Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J 17: 1555-1568.
28. Lidon-Moya MC, Barrera FN, Bueno M, Perez-Jimenez R, Sancho J, et al. (2005) An extensive thermodynamic characterization of the dimerization domain of the HIV-1 capsid protein. Protein Sci 14: 2387-2404.
29. Mateu MG, (2002) Conformational stability of dimeric and monomeric forms of the C-terminal domain of human immunodeficiency virus-1 capsid protein. J Mol Biol 318: 519-531.
30. del Alamo M, Rivas G, Mateu MG, (2005) Effect of macromolecular crowding agents on human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol 79: 14271-14281.
31. Holthauzen LM, Bolen DW, (2007) Mixed osmolytes: the degree to which one osmolyte affects the protein stabilizing ability of another. Protein Sci 16: 293-298.
32. Holthauzen LM, Rosgen J, Bolen DW, (2010) Hydrogen bonding progressively strengthens upon transfer of the protein urea-denatured state to water and protecting osmolytes. Biochemistry 49: 1310-1318.
33. Harries D, Rosgen J, (2008) A practical guide on how osmolytes modulate macromolecular properties. Methods Cell Biol 84: 679-735.
34. Street TO, Bolen DW, Rose GD, (2006) A molecular mechanism for osmolyte-induced protein stability. Proc Natl Acad Sci U S A 103: 13997-14002.
35. Arakawa T, Ejima D, Kita Y, Tsumoto K, (2006) Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764: 1677-1687.
36. Yancey PH, Clark ME, Hand SC, Bowlus RD, Somero GN, (1982) Living with water stress: evolution of osmolyte systems. Science 217: 1214-1222.
37. Yancey PH, (2004) Compatible and counteracting solutes: protecting cells from the Dead Sea to the deep sea. Sci Prog 87: 1-24.
38. Yancey PH, (2005) Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol 208: 2819-2830.
39. Yancey PH, Blake WR, Conley J, (2002) Unusual organic osmolytes in deep-sea animals: adaptations to hydrostatic pressure and other perturbants. Comp Biochem Physiol A Mol Integr Physiol 133: 667-676.
40. Yancey PH, Burg MB, (1990) Counteracting effects of urea and betaine in mammalian cells in culture. Am J Physiol 258: R198-204.
41. Yancey PH, Fyfe-Johnson AL, Kelly RH, Walker VP, Aunon MT, (2001) Trimethylamine oxide counteracts effects of hydrostatic pressure on proteins of deep-sea teleosts. J Exp Zool 289: 172-176.
42. Chaudhuri TK, Paul S, (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273: 1331-1349.
43. Sawkar AR, Schmitz M, Zimmer KP, Reczek D, Edmunds T, et al. (2006) Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol 1: 235-251.
44. Perlmutter DH, (2002) Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 52: 832-836.
45. Cohen FE, Kelly JW, (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426: 905-909.
46. Cho SS, Reddy G, Straub JE, Thirumalai D, (2011) Entropic stabilization of proteins by TMAO. J Phys Chem B 115: 13401-13407.
47. Qi W, Zhang A, Good TA, Fernandez EJ, (2009) Two disaccharides and trimethylamine N-oxide affect Abeta aggregation differently, but all attenuate oligomer-induced membrane permeability. Biochemistry 48: 8908-8919.
48. Yang DS, Yip CM, Huang TH, Chakrabartty A, Fraser PE, (1999) Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J Biol Chem 274: 32970-32974.
49. Nayak A, Lee CC, McRae GJ, Belfort G, (2009) Osmolyte controlled fibrillation kinetics of insulin: New insight into fibrillation using the preferential exclusion principle. Biotechnol Prog 25: 1508-1514.
50. Sukenik S, Harries D, (2012) Insights into the disparate action of osmolytes and macromolecular crowders on amyloid formation. Prion 6: 26-31.
51. Chow MKM, Devlin GL, Bottomley SP, (2001) Osmolytes as modulators of conformational changes in serpins. Biological Chemistry 382: 1593-1599.
52. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, et al. (1997) Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278: 849-853.
53. Fung J, Darabie AA, McLaurin J, (2005) Contribution of simple saccharides to the stabilization of amyloid structure. Biochem Biophys Res Commun 328: 1067-1072.
54. Sukenik S, Politi R, Ziserman L, Danino D, Friedler A, et al. (2011) Crowding alone cannot account for cosolute effect on amyloid aggregation. PLoS One 6: e15608.
55. Kim YS, Cape SP, Chi E, Raffen R, Wilkins-Stevens P, et al. (2001) Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J Biol Chem 276: 1626-1633.
56. Bolen DW, Baskakov IV, (2001) The osmophobic effect: natural selection of a thermodynamic force in protein folding. J Mol Biol 310: 955-963.
57. Chiti F, Dobson CM, (2009) Amyloid formation by globular proteins under native conditions. Nat Chem Biol 5: 15-22.
58. Ivanov D, Tsodikov OV, Kasanov J, Ellenberger T, Wagner G, et al. (2007) Domain-swapped dimerization of the HIV-1 capsid C-terminal domain. Proc Natl Acad Sci U S A 104: 4353-4358.